Physician profile
J Adam Kellman
NPI 1386624187
$11,348.54
in general payments reported to CMS, 2019-2025
55 companies · $1,957 in 2025
The $1,957 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,565 · 2020: $881 · 2021: $1,557 · 2022: $2,046 · 2023: $1,684 · 2024: $1,658 · 2025: $1,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,299.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,167.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,266.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,039.46 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $835.14 | 2019-2025 | Jardiance, Glyxambi |
| Abbvie INC. | $638.03 | 2021-2025 | |
| Pfizer INC. | $531.89 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $455.25 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $414.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $404.65 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $403.52 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $385.31 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $298.16 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $268.72 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $169.98 | 2019-2025 | Austedo Xr |
| Astellas Pharma US INC | $144.92 | 2019-2024 | Veozah |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Kellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.